Related Experiment Video
Updated: May 16, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Cyclophilin inhibitors for hepatitis C therapy
Fernando E Membreno1, Jennifer C Espinales, Eric J Lawitz
1Alamo Medical Research, San Antonio, TX 78215, USA. membreno@alamomedicalresearch.com
Clinics in Liver Disease
|November 27, 2012
Summary
New direct-acting antivirals offer a unique approach to hepatitis C therapy by targeting viral proteins. Cyclophilin inhibitors, a host-targeted agent, are advancing to phase 3 trials for potential hepatitis C cures.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- The landscape of hepatitis C treatment is rapidly evolving.
- Direct-acting antivirals (DAAs) targeting viral proteins have revolutionized therapy.
- Limited host-targeted agents have been in development.
Purpose of the Study:
- To review the emergence and potential of new direct-acting antivirals for hepatitis C.
- To discuss the role of host-targeted agents, specifically cyclophilin inhibitors, in future hepatitis C therapy.
- To highlight the progression of cyclophilin inhibitors into phase 3 clinical trials.
Main Methods:
- Review of recent advancements in antiviral drug development for hepatitis C.
- Analysis of mechanisms of action for direct-acting antivirals (protease, NS5A, NS5B inhibitors).
- Evaluation of the development status of host-targeted agents, focusing on cyclophilin inhibitors.
Main Results:
- New classes of direct-acting antivirals effectively inhibit viral replication by targeting specific viral proteins.
- Cyclophilin inhibitors represent the most advanced class of host-targeted agents currently in development.
- A cyclophilin inhibitor has advanced to phase 3 clinical trials, indicating significant therapeutic potential.
Conclusions:
- Direct-acting antivirals have transformed hepatitis C treatment paradigms.
- Host-targeted agents, particularly cyclophilin inhibitors, show promise for future hepatitis C cure strategies.
- The progression to phase 3 trials signifies a critical step towards novel hepatitis C therapies.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...